Turkey Slashes Prices Yet Again, Pharmas Prepare For Worst Case Scenario
This article was originally published in PharmAsia News
A third round of price cuts and substantial currency depreciation has manufacturers questioning investment in Turkey.
You may also be interested in...
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
The Turkish Social Security Institution or SGK hiked institutional pharmaceutical discounts with a new regulation in December 2010, imposing an additional 9.5% price cut to its reference pricing system
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.